- The global market for therapies for depressive and anxiety disorders was $28 billion in 2008. It increased to $29.4 billion in 2009. This is projected to reach $38.5 billion in 2014 at a compound annual growth rate (CAGR) of 5.6%

- Sales in antidepressants products were nearly $15.4 billion in 2008. It increased to $16.2 billion in 2009. This market is projected to reach $21.2 billion in 2014, for a 5-year CAGR of 5.5%.

- Sales in antianxiety drugs were nearly $12.6 billion in 2008. It increased to $13.2 billion in 2009. This market is projected to reach $17.3 billion in 2014, for a 5-year CAGR of 5.6%.

The objectives of the study are to present a comprehensive look at disorders that affect the mind, specifically that cause depression and anxiety. An overall discussion of mental disorders associated with depression and anxiety is presented along with an in-depth discovery of the various diseases and disorders that present significant problems for individuals and society. Markets are divided according to drug type because several products are used in many different disorders.

REASONS FOR STUDY

This study is presented to highlight the exciting area of mental health, specifically relating to depression and anxiety. Because in-depth study of the workings of the brain is a fairly new area of intense study, there are new and changing theories. The discovery of new mechanisms and chemicals in the brain has provided additional avenues for research and development of products that may alter the course of the diseases or modify the outcome. This study analyzes the current therapies for depression and anxiety and explores the new therapies that are in the pipeline to treat depression and anxiety. The study also addresses the many and varied issues and trends affecting the market. Because of the rapidly evolving climate of psychological disorders and the increasing knowledge of the workings of the brain, manufacturers of therapies for depressive and anxiety disorders must remain ever vigilant of the changing environment and strive to keep abreast of current and potential opportunities.

SCOPE OF STUDY

The report is designed to be a comprehensive business tool to provide an in-depth look at therapies for depression and anxiety. The geographic scope of the report is global with an emphasis on the United States. The report identifies the different disorders that manifest with depressive and anxiety symptoms; gives an explanation of the disorders; cites incidence; identifies specific drug types; presents current treatments, market size, and market participants; and presents potential treatments in research and development.

The market for therapies for depressive and anxiety disorders is divided into two areas:

* Therapies for depression
* Therapies for anxiety.

All markets are further broken down into specific types of products that are discussed in detail, measuring current and potential market size; identifying current and potential market drivers; detailing from 2006, 2007, 2008, 2009, and 2014; assessing current and potential competitors; and identifying current competitor market shares.